Shares of cancer drug developer KaloBios Pharmaceuticals rocketed higher Thursday after controversial investor Martin Shkreli led a group that took a majority stake in the company just after it had decided to wind down its operations.
KaloBios shares surged as high as $14.72 Thursday after the company said an investor group including Shkreli had acquired most of its stock. It made that announcement after the market closed on Wednesday.
Read Full Article »